VIMGF Stock Chart & Stats
$2.77
--
Market closed
$2.77
--
Day’s Range― - ―
52-Week Range$2.77 - $4.30
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
$1.84B
Enterprise Value$18.09K
Total Cash (Recent Filing)$51.74M
Total Debt (Recent Filing)$279.56M
Price to Earnings (P/E)43.9
Beta-0.09
Next Earnings
Oct 22, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding527,058,530
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)2.10
Price to Sales (P/S)3.45
P/FCF Ratio16.20
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.16Price Target Upside14.05% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)$48.64M
Bulls Say, Bears Say
Bulls Say
Margin Expansion / ProfitabilityOperating and net margins have expanded materially (EBIT margin ~13.1% in 2023/24 to ~16.7% TTM; net margin ~3.0% to ~8.5% TTM). Sustainable margin gains indicate improved cost structure and pricing power in veterinary products, supporting durable earnings even if top-line growth moderates.
Recurring B2B Revenue ModelThe business sells consumables, equipment and diagnostics to veterinary clinics with repeat reorder patterns and usage-based services. This B2B, repeat-demand model creates predictable revenue streams, higher customer stickiness, and structural resilience across market cycles.
Improving Balance Sheet LeverageLeverage has declined meaningfully (debt/equity ~0.34 vs ~0.60 in 2023), improving financial flexibility. Lower leverage reduces refinancing risk and gives capacity for targeted investments or M&A, supporting medium-term growth and operational resilience.
Bears Say
Cash Flow VolatilityCash generation is inconsistent: operating cash flow was negative in 2023 and free cash flow growth fell -18.9% TTM, with FCF roughly 0.87x of net income. This volatility signals sensitivity to working capital and investment timing, constraining capital allocation and increasing execution risk.
Slowing Revenue GrowthTop-line momentum has decelerated markedly (virtually flat in 2025 and modest TTM growth). With growth cooling, the company must rely more on margin gains to drive earnings. Prolonged sluggish revenue growth could limit scale economics and make results more sensitive to competition or pricing pressure.
Modest Return On EquityROE is still only mid-single-digit even after profit improvements, indicating the asset base or capital allocation hasn't translated into high shareholder returns. Persistent low returns can limit reinvestment payoff and make it harder to justify incremental capital without structural efficiency gains.
Vimian Group AB News
VIMGF FAQ
What was Vimian Group AB’s price range in the past 12 months?
Vimian Group AB lowest stock price was $2.77 and its highest was $4.30 in the past 12 months.
What is Vimian Group AB’s market cap?
Vimian Group AB’s market cap is $1.84B.
When is Vimian Group AB’s upcoming earnings report date?
Vimian Group AB’s upcoming earnings report date is Oct 22, 2026 which is in 94 days.
How were Vimian Group AB’s earnings last quarter?
Vimian Group AB released its earnings results on Jul 17, 2026. The company reported $0.023 earnings per share for the quarter, missing the consensus estimate of $0.031 by -$0.008.
Is Vimian Group AB overvalued?
According to Wall Street analysts Vimian Group AB’s price is currently Undervalued.
Does Vimian Group AB pay dividends?
Vimian Group AB does not currently pay dividends.
What is Vimian Group AB’s EPS estimate?
Vimian Group AB’s EPS estimate is 0.03.
How many shares outstanding does Vimian Group AB have?
Vimian Group AB has 527,058,530 shares outstanding.
What happened to Vimian Group AB’s price movement after its last earnings report?
Vimian Group AB reported an EPS of $0.023 in its last earnings report, missing expectations of $0.031. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vimian Group AB?
Currently, no hedge funds are holding shares in VIMGF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vimian Group AB
Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
VIMGF Stock 12 Month Forecast
Average Price Target
$3.16
▲(14.05% Upside)
Ownership Overview
―
Insiders
5.20% Mutual Funds
― Other Institutional Investors
92.93% Public Companies and
Individual Investors